Prostate cancer DNA vaccine - Genvax/University of Southampton

Drug Profile

Prostate cancer DNA vaccine - Genvax/University of Southampton

Alternative Names: Electroporation-delivered DNA vaccine against prostate cancer - Inovio/University of Southampton; GVX-3322

Latest Information Update: 11 May 2010

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator University of Southampton
  • Developer Genvax; University of Southampton
  • Class Cancer vaccines; DNA vaccines; Gene therapies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Prostate cancer

Most Recent Events

  • 05 Aug 2009 Immunogenicity data from a phase I/II trial in Prostate cancer released by Inovio
  • 18 Dec 2008 Interim immunogenicity & adverse events data from a phase I/II trial in Prostate cancer presented at the DNA Vaccines 2008 Conference (DNA Vaccines-2008)
  • 31 Oct 2005 Phase-I/II clinical trials in Prostate cancer in United Kingdom (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top